招股说明书
Altamira(CYTO)04-10 20:25
$Altamira(CYTO)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001213900-24-031737 Act: 33 Size: 357 KB 网页链接
简介:Altamira Therapeutics Ltd.成立于1998年。该公司的目标是成为一家领先的生物医药公司,专注于开发和商业化RNA递送技术。该公司认为,使用RNA疗法,无论是siRNA、mRNA还是其他类型来控制疾病相关基因的表达,前景广阔。通过利用小分子和蛋白质在其他方面“无法药效”的靶点,有望开辟治疗疑难杂症的RNA疗法的全新途径。
今开:1.64 | 昨收:1.64 |
最高:1.6999 | 最低:1.61 |
涨停价: | 跌停价: |
总市值:3696404 |
Altamira(CYTO)04-10 20:25
$Altamira(CYTO)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001213900-24-031737 Act: 33 Size: 357 KB 网页链接
医麦客03-28 10:35
2024年3月28日
医麦客新闻 eMedClub News
近日,Altamira Therapeutics宣布与Univercells Group达成合作协议,以评估该公司专有的、基于肽的SemaPhore平台在mRNA疫苗递送方面的应用,SemaPhore平台有望代替LNP递送系统,在mRNA领域中有广泛地应用潜力。如果实验成功,Univercells和Altam...
Altamira(CYTO)04-10 20:05
$Altamira(CYTO)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-24-031734 Act: 34 Size: 14 MB 网页链接
Altamira(CYTO)04-18 18:05
$Altamira(CYTO)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001012 Act: 33 Size: 2 KB 网页链接
Altamira(CYTO)04-18 04:25
$Altamira(CYTO)$ 424B4 Prospectus [Rule 424(b)(4)] Accession Number: 0001213900-24-033817 Act: 33 Size: 200 KB 网页链接
Altamira(CYTO)03-13 23:05
$Altamira(CYTO)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001213900-24-022034 Act: 34 Size: 35 KB 网页链接
Altamira(CYTO)04-23 04:45
$Altamira(CYTO)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-24-034940 Act: 34 Size: 14 MB 网页链接
Altamira(CYTO)04-17 05:05
$Altamira(CYTO)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-033500 Act: 34 Size: 477 KB 网页链接
Altamira(CYTO)04-10 20:25
$Altamira(CYTO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001213900-24-031738 Act: 33 Size: 112 KB 网页链接
Altamira(CYTO)04-10 20:35
$Altamira(CYTO)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-031741 Act: 34 Size: 102 KB 网页链接
医麦客03-28 10:35
2024年3月28日
医麦客新闻 eMedClub News
近日,Altamira Therapeutics宣布与Univercells Group达成合作协议,以评估该公司专有的、基于肽的SemaPhore平台在mRNA疫苗递送方面的应用,SemaPhore平台有望代替LNP递送系统,在mRNA领域中有广泛地应用潜力。如果实验成功,Univercells和Altam...查看全文
F1watch2023-07-05 18:20
F-1/A - Altamira Therapeutics Ltd. (0001601936) (Filer) Filed: 2023-07-05 AccNo: 0001213900-23-054243 Size: 1 MB 网页链接查看全文
F1watch2023-06-17 05:20
F-1 - Altamira Therapeutics Ltd. (0001601936) (Filer) Filed: 2023-06-16 AccNo: 0001213900-23-049716 Size: 500 KB 网页链接查看全文
稳妥的回报将军2023-06-16 09:18
上周多伦多证券交易所创业板(TSXV)涨幅最大的资源股是Solis Minerals、MacArthur Minerals、Altamira Gol、VR Resources和Tier One Silver。虽然大盘The S&P/TSX Venture Composite Index (INDEXTSI:JX)上周保持平稳,周五(6月9日)收于610.02点,但领涨的一只资源股的股价在短短五个交易日...查看全文
F1watch2023-06-02 04:40
F-1 - Altamira Therapeutics Ltd. (0001601936) (Filer) Filed: 2023-06-01 AccNo: 0001213900-23-045058 Size: 351 KB 网页链接查看全文
SeekingBiotech2023-05-24 21:44
$Altamira(CYTO)$
CYTO announced that its NASAR trial of Bentrio (AM-301) nasal spray met its primary endpoint查看全文
mx在隔壁2023-05-04 16:43
$Altamira(CYTO)$ 盘前黑马查看全文
医麦客2023-04-15 07:36
2023年4月15日/医麦客新闻 eMedClub News/--mRNA疫苗技术已发展数十年,研究历史可追溯至20世纪60年代,近两年来疫情的爆发及大流行大大加快了mRNA技术的成熟。目前上市的mRNA产品仅新冠疫苗一类,其他产品仍在临床开发中。近年来的临床研究已表明,mRNA疫苗在疾病预防和肿瘤治疗等多个领域具有巨...查看全文
F1watch2023-03-27 22:40
F-1/A - Altamira Therapeutics Ltd. (0001601936) (Filer) Filed: 2023-03-27 AccNo: 0001213900-23-023002 Size: 15 MB 网页链接查看全文
F1watch2023-03-13 21:20
F-1/A - Altamira Therapeutics Ltd. (0001601936) (Filer) Filed: 2023-03-13 AccNo: 0001213900-23-019406 Size: 15 MB 网页链接查看全文
$Altamira(CYTO)$ 20-F/A [Amend] Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-24-034940 Act: 34 Size: 14 MB 网页链接
$Altamira(CYTO)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001012 Act: 33 Size: 2 KB 网页链接
$Altamira(CYTO)$ 424B4 Prospectus [Rule 424(b)(4)] Accession Number: 0001213900-24-033817 Act: 33 Size: 200 KB 网页链接
$Altamira(CYTO)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-033500 Act: 34 Size: 477 KB 网页链接
$Altamira(CYTO)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-031741 Act: 34 Size: 102 KB 网页链接
$Altamira(CYTO)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001213900-24-031738 Act: 33 Size: 112 KB 网页链接
$Altamira(CYTO)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001213900-24-031737 Act: 33 Size: 357 KB 网页链接
$Altamira(CYTO)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-24-031734 Act: 34 Size: 14 MB 网页链接
$Altamira(CYTO)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001213900-24-022034 Act: 34 Size: 35 KB 网页链接
$Altamira(CYTO)$ 424B4 Prospectus [Rule 424(b)(4)] Accession Number: 0001213900-24-005353 Act: 33 Size: 129 KB 网页链接